文献速递妇科

HOXA4/HOXB3基因表达特征作为高级别浆液性卵巢癌初次肿瘤细胞减灭术和一线辅助化疗后复发生物标志物

HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
PubMed 文献 · Gynecol Oncol · 2018-01-01

研究在高级别浆液性卵巢癌(HGSOC)中筛选与无进展生存期(PFS)相关的HOX基因,用训练队列(n=71)建立HOXA4/HOXB3风险评分模型,并在TCGA独立队列(n=320)验证。多因素分析显示HOXA4过表达(HR=1.20)和HOXB3过表达(HR=1.09)与更短PFS显著相关;高风险评分组中位PFS为16.9个月,低风险组未达到(>80个月)(HR=8.89)。体外实验显示过表达HOXA4或HOXB3降低卵巢癌细胞对顺铂的敏感性并减弱顺铂诱导的ROS产生。

要点

  • HOXA4过表达(HR=1.20)和HOXB3过表达(HR=1.09)与HGSOC患者更短PFS显著相关。
  • 基于HOXA4/HOXB3风险评分,高风险组中位PFS为16.9个月,低风险组未达到(>80个月),HR=8.89。
  • TCGA队列中HOXA4/HOXB3风险评分与无病生存期显著相关(HR=1.44)。

核心结论

  • 基于HOXA4/HOXB3基因表达的风险评分可能有助于HGSOC患者的预后风险分层,并需前瞻性验证。

研究设计与样本

  • 研究在发现队列的初治HGSOC样本RNA测序数据中筛选与PFS相关的HOX基因,并在独立训练队列(n=71)中进行qPCR检测。
  • 使用单因素和多因素Cox回归建立PFS预后模型,并将患者按风险分组。
  • 模型在癌症基因组图谱(TCGA)独立HGSOC队列(n=320)中验证。
  • 体外实验检测选定HOX基因对药物敏感性和活性氧(ROS)积累的影响。

主要发现

  • 在训练队列检测的23个HOX基因中,多因素分析显示HOXA4过表达(HR=1.20,95%CI=1.07-1.34,P=0.002)和HOXB3过表达(HR=1.09,95%CI=1.01-1.17,P=0.027)与更短PFS显著相关。
  • 基于HOXA4/HOXB3风险评分的最佳截断值,高风险评分患者中位PFS为16.9个月(95%CI=14.6-21.2个月),低风险评分患者未达到(>80个月)(HR=8.89,95%CI=2.09-37.74,P<0.001)。
  • 在TCGA队列中,HOXA4/HOXB3风险评分与无病生存期显著相关(HR=1.44,95%CI=1.00-2.09,P=0.048)。
  • 体外实验显示,卵巢癌细胞中过表达HOXA4或HOXB3降低了对顺铂的敏感性并减弱了顺铂诱导的ROS产生(P<0.05)。

临床怎么用

  • 作者认为,基于HOXA4/HOXB3基因表达的风险评分可能有助于HGSOC患者的预后风险分层,并需前瞻性验证。

局限性

  • 原文结论指出该风险评分需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Aberrant homeobox (HOX) gene expression is reported in high-grade serous ovarian carcinoma (HGSOC), however, its prognostic significance remains unclear. METHODS: HOX genes associated with progression-free survival (PFS) in a discovery cohort of primary HGSOC samples with RNA sequencing data, and those previously reported to be associated with clinical outcomes, were selected for qPCR testing in an independent training cohort of primary HGSOC samples (n=71). A prognostic model for PFS was developed using univariate and multivariate Cox regression. Patients were stratified into risk groups that optimized the test statistic. The model was tested in an independent HGSOC cohort from The Cancer Genome Atlas (TCGA) (n=320). The effect of selected HOX genes on drug sensitivity and reactive oxygen species (ROS) accumulation was examined in vitro. RESULTS: Of 23 HOX genes tested in the training cohort, HOXA4 (HR=1.20, 95% CI=1.07-1.34, P=0.002) and HOXB3 (HR=1.09, 95% CI=1.01-1.17, P=0.027) overexpression were significantly associated with shorter PFS in multivariate analysis. Based on the optimal cutoff of the HOXA4/HOXB3 risk score, median PFS was 16.9months (95% CI=14.6-21.2months) and not reached (>80months) for patients with high and low risk scores, respectively (HR=8.89, 95% CI=2.09-37.74, P<0.001). In TCGA, the HOXA4/HOXB3 risk score was significantly associated with disease-free survival (HR=1.44, 95% CI=1.00-2.09, P=0.048). HOXA4 or HOXB3 overexpression in ovarian cancer cells decreased sensitivity to cisplatin and attenuated the generation of cisplatin-induced ROS (P<0.05). CONCLUSIONS: HOXA4/HOXB3 gene expression-based risk score may be useful for prognostic risk stratification and warrants prospective validation in HGSOC patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Miller KR, Patel JN, Zhang Q, et al. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy. Gynecol Oncol. 2018. PMID: 29402501. doi:10.1016/j.ygyno.2018.01.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。